Safety and efficacy of tandem Autologous-Allogeneic peripheral blood stem cell transplantation in patients with multiple myeloma relapsing after a first high dose therapy
Not Applicable
Recruiting
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000040635
- Lead Sponsor
- Department of hematology, Tokyo-kita Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1.Uncontrolled active infection. 2.Cardiac amyloidosis. 3.Patient who is judged to be medically unfit by his/her physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Non-relapse mortality(NRM) at 100 days after allogeneic peripheral blood stem cell transplantation
- Secondary Outcome Measures
Name Time Method Adverse event Engraftment Response rate NRM at 1-,2-,and 3-years Acute and chronic GVHD Relapse rate Progression free survival Overall survival